Mathematical and theoretical biology

Certara Acquires Applied BioMath Expanding Its Biosimulation Portfolio to Industrialize New Capabilities for Optimal Dosing for Novel Therapies

Retrieved on: 
星期三, 十二月 13, 2023
Drug, QSP, Drug development, Prevalence, AI, Mathematical and theoretical biology, Biomarker, Toxicity, Pharmaceutical industry

Nine out of ten new therapies that enter the clinic do not achieve regulatory approval or commercialization primarily due to lack of efficacy or unmanageable toxicity.

Key Points: 
  • Nine out of ten new therapies that enter the clinic do not achieve regulatory approval or commercialization primarily due to lack of efficacy or unmanageable toxicity.
  • The popularity and prevalence of the QSP methodology has grown in recent years as a strategy to de-risk drug development.
  • “Together, Applied BioMath and Certara have the scientific and computational expertise to industrialize QSP biosimulation methods,” said William F. Feehery, CEO of Certara.
  • Biology-Focused Drug Development: As drug development becomes more biology-focused, the combined team will build more reusable models to optimize novel and combination therapies for groundbreaking results.

Applied BioMath, LLC Named a Top Place to Work in Massachusetts by The Boston Globe

Retrieved on: 
星期四, 十一月 30, 2023
R, Doctor of Philosophy, Mathematical and theoretical biology, Engineering, Software, Science, Pharmaceutical industry, Management

Founded in 2013, Applied BioMath's mission is to develop engineering, science, and software that revolutionizes drug invention.

Key Points: 
  • Founded in 2013, Applied BioMath's mission is to develop engineering, science, and software that revolutionizes drug invention.
  • Over 90% of Applied BioMath employees completed the anonymous survey which assessed categories such as company direction, management, workplace experience, and pay and benefits.
  • "To be named a Top Place to Work in Massachusetts by The Boston Globe is a testament to our  people-centric culture that supports our team members in bringing their authentic selves to work," said John Burke, PhD, Co-founder, President and CEO of Applied BioMath.
  • To learn more and view the full list of the 2023 Top Places to Work, visit https://www.bostonglobe.com/magazine/top-places-work/2023/ .

Applied BioMath, LLC Announces Participation at the 14th American Conference on Pharmacometrics

Retrieved on: 
星期四, 十一月 2, 2023
Association of Applied Biologists, Mathematical and theoretical biology, American Conference, Conference, Doctor of Philosophy, R, EFA, Statistics, National Harbor, Maryland, Tourism, Management, MD

Applied BioMath will host a pre-conference workshop entitled, "Practical Application of MID3 to Inform Early Drug Discovery Decisions Using Applied BioMath Assess™" on Sunday, November 5th from 1:00 - 5:00p.m.

Key Points: 
  • Applied BioMath will host a pre-conference workshop entitled, "Practical Application of MID3 to Inform Early Drug Discovery Decisions Using Applied BioMath Assess™" on Sunday, November 5th from 1:00 - 5:00p.m.
  • The workshop will provide an understanding of the Early Feasibility Assessment (EFA) methodology and teach participants how to use Applied BioMath Assess™ to gain insight into project feasibility early in R&D.
  • "We are looking forward to the pre-conference workshop, poster presentations, and celebrating the achievement of Dr. Rendary at ACoP14," said John Burke, PhD, Co-founder, President and CEO of Applied BioMath.
  • "The scientific program highlights the advances of quantitative approaches in drug and therapeutic R&D and we look forward to the scientific discussions with the attendees."

Applied BioMath, LLC Presents Quantitative Systems Pharmacology Model of T-cell Engagers for Solid Tumors at the Society for Immunotherapy of Cancer Annual Meeting

Retrieved on: 
星期一, 十月 30, 2023
American Board of Applied Toxicology, Mathematical and theoretical biology, Trial of the century, Therapy, Bivalent (genetics), Doctor of Philosophy, QSP, R, Mall of America, SITC, Immunotherapy, Bi-specific T-cell engager, Engagers, Drug discovery, Trichloroethylene, Society, Cancer, Therapeutic index, Pharmaceutical industry, Vaccine

During the conference, Fei Hua, PhD, Vice President of Modeling and Simulation Services at Applied BioMath, will present the poster entitled, "Overcoming the dose-response prediction limitation from bench to clinic for T-cell engagers: Using Quantitative Systems Pharmacology (QSP) modeling in the development of CDR404 for solid tumors."

Key Points: 
  • During the conference, Fei Hua, PhD, Vice President of Modeling and Simulation Services at Applied BioMath, will present the poster entitled, "Overcoming the dose-response prediction limitation from bench to clinic for T-cell engagers: Using Quantitative Systems Pharmacology (QSP) modeling in the development of CDR404 for solid tumors."
  • While T-cell Engagers (TCEs) offer a potentially very potent approach to treat cancer, they also have complex relationships between binding potency, exposure, and efficacy.
  • "For therapeutics with complex mechanisms of action (MoA), QSP modeling can be integral for progressing through the R&D pipeline," said John Burke, PhD, Co-founder, President and CEO.
  • "Particularly for TCEs, we've had experience where QSP modeling has tested target feasibility, optimized molecule design, predicted therapeutic index, and guided clinical trial design."

Marissa Renardy, PhD, of Applied BioMath, Receives ISoP Emerging Scientist Award

Retrieved on: 
星期五, 十月 20, 2023
Harvard John A. Paulson School of Engineering and Applied Sciences, Mathematical and theoretical biology, OH, BS, MD, Doctor of Philosophy, Research, R, Statistics, COVID-19, Doctor of Pharmacy, Ohio State University, Utta Isop, University, Tuberculosis, Immunology, MS, Pharmaceutical industry, Microbiology, Mathematics, Virginia Tech

CONCORD, Mass., Oct. 20, 2023 /PRNewswire/ -- Applied BioMath ( www.appliedbiomath.com ), the industry-leader in providing model-informed drug discovery and development (MID3) support to help accelerate and de-risk therapeutic research and development (R&D), today announced Marissa Renardy, PhD, Principal Scientist at Applied BioMath received ISoP's Emerging Scientist Award.

Key Points: 
  • CONCORD, Mass., Oct. 20, 2023 /PRNewswire/ -- Applied BioMath ( www.appliedbiomath.com ), the industry-leader in providing model-informed drug discovery and development (MID3) support to help accelerate and de-risk therapeutic research and development (R&D), today announced Marissa Renardy, PhD, Principal Scientist at Applied BioMath received ISoP's Emerging Scientist Award.
  • Dr. Renardy will be recognized at the ACoP14 opening session and ISoP award's ceremony on Sunday, November 5, 2023.
  • The ISoP Emerging Scientist Award recognizes early-career scientists who are within five years of earning their MS, PharmD, PhD, or MD degree, and have made extraordinary impact in the fields of pharmacometrics, applied statistics, systems-based modeling and simulation, or a related scientific area.
  • "This is a very well-deserved recognition for Dr. Renardy," said John Burke, PhD, Co-founder, President and CEO of Applied BioMath.

Applied BioMath, LLC Announces Participation at AAPS 2023 PharmSci 360

Retrieved on: 
星期四, 十月 19, 2023
Drug development, Science, Patient, Harvard John A. Paulson School of Engineering and Applied Sciences, Mathematical and theoretical biology, CSO, Bi-specific T-cell engager, Simulation, Doctor of Philosophy, AAPS, R, National Center for Advancing Translational Sciences, Messenger, UGT1A1, Biomarker, Translation, Crigler–Najjar syndrome, Pharmaceutical industry, Medical imaging, Management, Medical device

CONCORD, Mass., Oct. 19, 2023 /PRNewswire/ -- Applied BioMath ( www.appliedbiomath.com ), the industry-leader in providing model-informed drug discovery and development (MID3) support to help accelerate and de-risk therapeutic research and development (R&D), today announced their participation at AAPS 2023 PharmSci 360 occurring October 22-25, 2023 in Orlando, FL.

Key Points: 
  • CONCORD, Mass., Oct. 19, 2023 /PRNewswire/ -- Applied BioMath ( www.appliedbiomath.com ), the industry-leader in providing model-informed drug discovery and development (MID3) support to help accelerate and de-risk therapeutic research and development (R&D), today announced their participation at AAPS 2023 PharmSci 360 occurring October 22-25, 2023 in Orlando, FL.
  • Applied BioMath will participate in multiple presentations during the conference.
  • Joshua Apgar, PhD, Co-founder and CSO at Applied BioMath will give a Speaker Spotlight presentation entitled, "Evolving Clinical Pharmacology and Translational PK/PD Approaches for New Modalities" on Tuesday, October 24th from 9:30-10:30am.
  • To learn more about Applied BioMath, visit www.appliedbiomath.com .

Applied BioMath, LLC Hosts 6th Annual Quantitative Systems Pharmacology Summit

Retrieved on: 
星期二, 九月 26, 2023
Kiko, Learning, Postdoctoral researcher, GSK, University at Buffalo, University, Therapy, CRS, Quantitative systems pharmacology, QSP, SLE, Doctor of Philosophy, Mathematical and theoretical biology, R, Systems pharmacology, Pharmaceutical industry

CONCORD, Mass., Sept. 26, 2023 /PRNewswire/ -- Applied BioMath ( www.appliedbiomath.com ), the industry-leader in providing model-informed drug discovery and development (MID3) support to help accelerate and de-risk therapeutic research and development (R&D), today announced the full speaker lineup for their Quantitative Systems Pharmacology (QSP) Summit occurring Thursday, October 12, 2023 in Cambridge, MA.

Key Points: 
  • CONCORD, Mass., Sept. 26, 2023 /PRNewswire/ -- Applied BioMath ( www.appliedbiomath.com ), the industry-leader in providing model-informed drug discovery and development (MID3) support to help accelerate and de-risk therapeutic research and development (R&D), today announced the full speaker lineup for their Quantitative Systems Pharmacology (QSP) Summit occurring Thursday, October 12, 2023 in Cambridge, MA.
  • The speakers at the 6th annual QSP Summit are:
    Rajat Desikan, PhD, Director, Quantitative Clinical Pharmacology at GSK in collaboration with Tianjing (Kiko) Ren, PhD, Postdoctoral Fellow at University of Buffalo and GSK
    "Preclinical modeling of an IgG cleaving enzyme: A solution to a unique problem"
    "Exploring Immune Cell Dynamics with QSP Modeling: Case Studies in SLE and CRS"
    "I am thrilled with our speaker lineup," said John Burke, PhD, Co-founder, President and CEO of Applied BioMath.
  • "By gathering this community and learning from one another, we hope to make an impact on developing better therapeutics."
  • To learn more and register for the QSP Summit, visit https://www.appliedbiomath.com/qsp-summit-cambridge-2023 .

Applied BioMath, LLC Presents Mathematical Modeling to Optimize Therapeutic Window at the 14th Annual World Bispecific Summit

Retrieved on: 
星期四, 九月 21, 2023
Bispecific monoclonal antibody, Therapy, Applied Biosystems, Doctor of Philosophy, Translation, Biophysics, Mathematical and theoretical biology, Avidity, R, Pharmaceutical industry, Management

Fei Hua, PhD, Vice President of Modeling and Simulation Services at Applied BioMath will present, "Using Mathematical Modeling to Find a Balance Between Affinity and Avidity for an Optimal Therapeutic Window" within the Preclinical and Clinical Track on Tuesday, October 3, 2023 at 2:15pm.

Key Points: 
  • Fei Hua, PhD, Vice President of Modeling and Simulation Services at Applied BioMath will present, "Using Mathematical Modeling to Find a Balance Between Affinity and Avidity for an Optimal Therapeutic Window" within the Preclinical and Clinical Track on Tuesday, October 3, 2023 at 2:15pm.
  • In this presentation, Dr. Hua will demonstrate how mathematical modeling can help address critical design and development considerations, and predict an optimal therapeutic window for bispecific molecules.
  • For example, with cis-binding bispecific molecules, weaker single-target binding affinity with stronger avidity is a strategy to reduce the chances of the drug binding to off-target cells, thereby increasing the therapeutic window.
  • "Incorporating mathematical modeling approaches provides competitive advantages, as it helps to test and generate hypotheses much more quickly than traditional methods."

Applied BioMath, LLC Awarded Grant by the National Institutes of Health for a Simulation Platform to Predict Dose and Therapeutic Window of Immunocytokines

Retrieved on: 
星期二, 八月 8, 2023
Communication, RA, Drug development, Therapy, IC, Cancer, Applied kinesiology, QSP, Toxicity, ICS, Doctor of Philosophy, Bangladesh Technical Education Board, Psoriasis, Patient, Risk, HPC, Mathematical and theoretical biology, R, Safety, Infection, Rheumatoid arthritis, Pharmaceutical industry

Immunocytokines (ICs) are a promising class of cytokine-based therapeutics with potential applications in diseases such as rheumatoid arthritis (RA), psoriasis, and cancer.

Key Points: 
  • Immunocytokines (ICs) are a promising class of cytokine-based therapeutics with potential applications in diseases such as rheumatoid arthritis (RA), psoriasis, and cancer.
  • However, achieving an adequate therapeutic window is complicated because of the potentially high risk of toxicity due to off-target effects.
  • The grant referenced in this press release is supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under Award Number R44AI177133.
  • The content is solely the responsibility of Applied BioMath, LLC and does not necessarily represent the official views of the National Institutes of Health.

Applied BioMath, LLC Presents Quantitative Systems Pharmacology Model of Lipid Nanoparticle mRNA Delivery at the mRNA-Based Therapeutics Summit

Retrieved on: 
星期二, 七月 18, 2023
Therapeutic index, Translation, R, LNP, QSP, Safety, Treatment, Doctor of Philosophy, Messenger, Mathematical and theoretical biology, Pharmaceutical industry, Vaccine, Applied Biosystems, Biology

Diana Marcantonio, PhD, Director of Biology at Applied BioMath will present, "Applications of a Quantitative Systems Pharmacology (QSP) Model of Lipid Nanoparticle (LNP) mRNA delivery for the Treatment of Crigler-Najjar Syndrome Type 1" on Friday, July 28th at 2:30 p.m. in the afternoon session of the Translation track.

Key Points: 
  • Diana Marcantonio, PhD, Director of Biology at Applied BioMath will present, "Applications of a Quantitative Systems Pharmacology (QSP) Model of Lipid Nanoparticle (LNP) mRNA delivery for the Treatment of Crigler-Najjar Syndrome Type 1" on Friday, July 28th at 2:30 p.m. in the afternoon session of the Translation track.
  • Applied BioMath Assess™ is a point-and-click, MID3 software to assess efficacy, safety, and therapeutic index for early stage biotherapeutics.
  • "In this presentation we hope to demonstrate how modeling and simulation approaches can be applied throughout the R&D pipeline," said John Burke, PhD, Co-founder, President and CEO of Applied BioMath.
  • To learn more about Applied BioMath, visit www.appliedbiomath.com .